{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T21:25:04Z","timestamp":1777325104893,"version":"3.51.4"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T00:00:00Z","timestamp":1603152000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Methods & Clinical Development"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.omtm.2020.10.016","type":"journal-article","created":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T10:25:57Z","timestamp":1603448757000},"page":"1-17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Systemic Treatment of Fabry Disease Using a Novel AAV9 Vector Expressing \u03b1-Galactosidase A"],"prefix":"10.1016","volume":"20","author":[{"given":"Maria Grazia","family":"Biferi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathilde","family":"Cohen-Tannoudji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Garc\u00eda-Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Souto-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Vi\u00e9itez-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"San-Mill\u00e1n-Tejado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Fern\u00e1ndez-Carrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tania","family":"P\u00e9rez-M\u00e1rquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana","family":"Teijeira-Bautista","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soraya","family":"Barrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanesa","family":"Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thibaut","family":"Marais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1frica","family":"Gonz\u00e1lez-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martine","family":"Barkats","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saida","family":"Ortolano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2020.10.016_bib1","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ymgme.2016.05.015","article-title":"Pilot study of newborn screening for six lysosomal storage diseases using Tandem Mass Spectrometry","volume":"118","author":"Elliott","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.omtm.2020.10.016_bib2","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jpeds.2014.09.023","article-title":"Lysosomal storage disorder screening implementation: findings from the first six months of full population pilot testing in Missouri","volume":"166","author":"Hopkins","year":"2015","journal-title":"J.\u00a0Pediatr."},{"key":"10.1016\/j.omtm.2020.10.016_bib3","series-title":"Fabry Disease","first-page":"181","article-title":"Clinical manifestations of Fabry disease: an overview","author":"Mehta","year":"2010"},{"key":"10.1016\/j.omtm.2020.10.016_bib4","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00109-005-0656-2","article-title":"Relationship between X-inactivation and clinical involvement in Fabry heterozygotes. Eleven novel mutations in the \u03b1-galactosidase A gene in the Czech and Slovak population","volume":"83","author":"Dobrovolny","year":"2005","journal-title":"J.\u00a0Mol. Med. (Berl.)"},{"key":"10.1016\/j.omtm.2020.10.016_bib5","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000448968","article-title":"Long Term Treatment with Enzyme Replacement Therapy in Patients with Fabry Disease","volume":"134","author":"Oder","year":"2016","journal-title":"Nephron"},{"key":"10.1016\/j.omtm.2020.10.016_bib6","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry\u2019s Disease with the Pharmacologic Chaperone Migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"R1","key":"10.1016\/j.omtm.2020.10.016_bib7","doi-asserted-by":"crossref","first-page":"R65","DOI":"10.1093\/hmg\/ddv457","article-title":"Gene therapy for lysosomal storage disorders: a good start","volume":"25","author":"Biffi","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtm.2020.10.016_bib8","first-page":"1","article-title":"Small molecules: Substrate inhibitors, chaperones, stop-codon read through, and beyond","volume":"4","author":"Ortolano","year":"2016","journal-title":"JIEMS"},{"key":"10.1016\/j.omtm.2020.10.016_bib9","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/BF00219337","article-title":"Quantitative correlation between the residual activity of \u03b2-hexosaminidase A and arylsulfatase A and the severity of the resulting lysosomal storage disease","volume":"88","author":"Leinekugel","year":"1992","journal-title":"Hum. Genet."},{"key":"10.1016\/j.omtm.2020.10.016_bib10","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1542\/peds.2005-2895","article-title":"Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease","volume":"118","author":"Ries","year":"2006","journal-title":"Pediatrics"},{"key":"10.1016\/j.omtm.2020.10.016_bib11","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2174\/187221412799015245","article-title":"Present and future of adeno associated virus based gene therapy approaches","volume":"6","author":"Ortolano","year":"2012","journal-title":"Recent Pat. Endocr. Metab. Immune Drug Discov."},{"key":"10.1016\/j.omtm.2020.10.016_bib12","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","article-title":"Emerging Issues in AAV-Mediated In\u00a0Vivo Gene Therapy","volume":"8","author":"Colella","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2020.10.016_bib13","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ymgme.2008.10.017","article-title":"Long-term inhibition of glycosphingolipid accumulation in Fabry model mice by a single systemic injection of AAV1 vector in the neonatal period","volume":"96","author":"Ogawa","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.omtm.2020.10.016_bib14","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ymthe.2003.11.015","article-title":"AAV2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of \u03b1-galactosidase A and the induction of immune tolerance in Fabry mice","volume":"9","author":"Ziegler","year":"2004","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2020.10.016_bib15","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/sj.mt.6300066","article-title":"Correction of the biochemical and functional deficits in Fabry mice following AAV8-mediated hepatic expression of \u03b1-galactosidase A","volume":"15","author":"Ziegler","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2020.10.016_bib16","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1182\/blood-2014-12-615492","article-title":"In\u00a0vivo genome editing of the albumin locus as a platform for protein replacement therapy","volume":"126","author":"Sharma","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2020.10.016_bib17","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.omtm.2017.05.003","article-title":"Lentivector Iterations and Pre-Clinical Scale-Up\/Toxicity Testing: Targeting Mobilized CD34+ Cells for Correction of Fabry Disease","volume":"5","author":"Huang","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2020.10.016_bib18","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1212\/01.WNL.0000166000.24321.4F","article-title":"Effect of genetic modifiers on cerebral lesions in Fabry disease","volume":"64","author":"Altarescu","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.omtm.2020.10.016_bib19","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.jstrokecerebrovasdis.2013.08.010","article-title":"Prevalence of Fabry disease in stroke patients--a systematic review and meta-analysis","volume":"23","author":"Shi","year":"2014","journal-title":"J.\u00a0Stroke Cerebrovasc. Dis."},{"key":"10.1016\/j.omtm.2020.10.016_bib20","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1161\/STROKEAHA.108.526293","article-title":"Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry","volume":"40","author":"Sims","year":"2009","journal-title":"Stroke"},{"key":"10.1016\/j.omtm.2020.10.016_bib21","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nbt.1515","article-title":"Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes","volume":"27","author":"Foust","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtm.2020.10.016_bib22","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/mt.2009.71","article-title":"Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons","volume":"17","author":"Duque","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2020.10.016_bib23","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1016\/j.ymthe.2017.05.017","article-title":"A New AAV10-U7-Mediated Gene Therapy Prolongs Survival and Restores Function in an ALS Mouse Model","volume":"25","author":"Biferi","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2020.10.016_bib24","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1073\/pnas.94.6.2540","article-title":"\u03b1-Galactosidase A deficient mice: a model of Fabry disease","volume":"94","author":"Ohshima","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2020.10.016_bib25","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.ajpath.2014.11.004","article-title":"\u03b1-Galactosidase A knockout mice: progressive organ pathology resembles the type 2 later-onset phenotype of Fabry disease","volume":"185","author":"Bangari","year":"2015","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.omtm.2020.10.016_bib26","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2020.10.016_bib27","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s40265-019-01162-5","article-title":"Onasemnogene Abeparvovec: First Global Approval","volume":"79","author":"Hoy","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.omtm.2020.10.016_bib28","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.3390\/toxins2081997","article-title":"Distribution of Gb(3) Immunoreactivity in the Mouse Central Nervous System","volume":"2","author":"Obata","year":"2010","journal-title":"Toxins (Basel)"},{"key":"10.1016\/j.omtm.2020.10.016_bib29","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.nbd.2008.09.001","article-title":"Neurophysiological, behavioral and morphological abnormalities in the Fabry knockout mice","volume":"33","author":"Rodrigues","year":"2009","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.omtm.2020.10.016_bib30","doi-asserted-by":"crossref","first-page":"e39300","DOI":"10.7554\/eLife.39300","article-title":"Characterization of small fiber pathology in a mouse model of Fabry disease","volume":"7","author":"Hofmann","year":"2018","journal-title":"eLife"},{"key":"10.1016\/j.omtm.2020.10.016_bib31","doi-asserted-by":"crossref","first-page":"e0180601","DOI":"10.1371\/journal.pone.0180601","article-title":"Affective and cognitive behavior in the alpha-galactosidase A deficient mouse model of Fabry disease","volume":"12","author":"Hofmann","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omtm.2020.10.016_bib32","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s10157-017-1525-3","article-title":"Plasma lyso-Gb3: a biomarker for monitoring fabry patients during enzyme replacement therapy","volume":"22","author":"Sakuraba","year":"2018","journal-title":"Clin. Exp. Nephrol."},{"key":"10.1016\/j.omtm.2020.10.016_bib33","series-title":"Rosenberg\u2019s Molecular and Genetic Basis of Neurological and Psychiatric Disease","first-page":"575","article-title":"Fabry disease: \u03b1-galactosidase A deficiency","author":"Desnick","year":"2020"},{"key":"10.1016\/j.omtm.2020.10.016_bib34","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/BF00697017","article-title":"Neuropathological and biochemical studies in Fabry\u2019s disease","volume":"30","author":"Tabira","year":"1974","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.omtm.2020.10.016_bib35","first-page":"27","article-title":"Parkinson\u2019s disease prevalence in Fabry disease: A survey study","volume":"14","author":"Wise","year":"2017","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.omtm.2020.10.016_bib36","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1038\/mt.2011.119","article-title":"Systemic administration of AAV8-\u03b1-galactosidase A induces humoral tolerance in nonhuman primates despite low hepatic expression","volume":"19","author":"Nietupski","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2020.10.016_bib37","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1086\/376608","article-title":"Fabry disease: novel \u03b1-galactosidase A 3\u2032-terminal mutations result in multiple transcripts due to aberrant 3\u2032-end formation","volume":"73","author":"Yasuda","year":"2003","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.omtm.2020.10.016_bib38","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1089\/hum.2019.012","article-title":"Safe and Sustained Expression of Human Iduronidase After Intrathecal Administration of Adeno-Associated Virus Serotype 9 in Infant Rhesus Monkeys","volume":"30","author":"Hordeaux","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2020.10.016_bib39","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1089\/hum.2016.184","article-title":"Prevention of neurocognitive deficiency in mucopolysaccharidosis Type II mice by central nervous system-directed, AAV9-mediated iduronate sulfatase gene transfer","volume":"28","author":"Laoharawee","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2020.10.016_bib40","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1089\/hum.2017.187","article-title":"Intranasal Adeno-Associated Virus Mediated Gene Delivery and Expression of Human Iduronidase in the Central Nervous System: A Noninvasive and Effective Approach for Prevention of Neurologic Disease in Mucopolysaccharidosis Type I","volume":"28","author":"Belur","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2020.10.016_bib41","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/jbmr.3734","article-title":"Gaucher Disease in Bone: From Pathophysiology to Practice","volume":"34","author":"Hughes","year":"2019","journal-title":"J.\u00a0Bone Miner. Res."},{"key":"10.1016\/j.omtm.2020.10.016_bib42","first-page":"e16","article-title":"Orthopedic challenges in patients with mucopolysaccharidoses type II (Hunter syndrome) enrolled in the Hunter Outcome Survey (HOS)","volume":"2","author":"Link","year":"2010","journal-title":"Orthop. Rev."},{"key":"10.1016\/j.omtm.2020.10.016_bib43","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1016\/j.ymthe.2020.05.011","article-title":"AAV9-Mediated Expression of SMN Restricted to Neurons Does Not Rescue the Spinal Muscular Atrophy Phenotype in Mice","volume":"28","author":"Besse","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2020.10.016_bib44","series-title":"Zolgensma\u00ae data shows rapid, significant, clinically meaningful benefit in SMA including prolonged event free survival, motor milestone achievement and durability now up to 5 years post-dosing","year":"2020"},{"key":"10.1016\/j.omtm.2020.10.016_bib45","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1084\/jem.139.2.249","article-title":"Maturation of the humoral immune response in mice","volume":"139","author":"Spear","year":"1974","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.omtm.2020.10.016_bib46","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.celrep.2019.07.047","article-title":"Maternal Antibodies Inhibit Neonatal and Infant Responses to Vaccination by Shaping the Early-Life B Cell Repertoire within Germinal Centers","volume":"28","author":"Vono","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.omtm.2020.10.016_bib47","series-title":"Letter to the XLMTM Patient Community","year":"2020"},{"key":"10.1016\/j.omtm.2020.10.016_bib48","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2147\/DDDT.S36131","article-title":"Multicomponent nanoparticles as nonviral vectors for the treatment of Fabry disease by gene therapy","volume":"6","author":"Ruiz de Garibay","year":"2012","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.omtm.2020.10.016_bib49","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3389\/fnmol.2015.00036","article-title":"Systemic AAVrh10 provides higher transgene expression than AAV9 in the brain and the spinal cord of neonatal mice","volume":"8","author":"Tanguy","year":"2015","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.omtm.2020.10.016_bib50","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0009-8981(01)00478-8","article-title":"Fabry disease: enzymatic diagnosis in dried blood spots on filter paper","volume":"308","author":"Chamoles","year":"2001","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.omtm.2020.10.016_bib51","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ymgme.2016.10.006","article-title":"Plasma LysoGb3: A useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes","volume":"120","author":"Nowak","year":"2017","journal-title":"Mol. Genet. Metab."}],"container-title":["Molecular Therapy - Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050120302205?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050120302205?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T09:30:38Z","timestamp":1762421438000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050120302205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":51,"alternative-id":["S2329050120302205"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2020.10.016","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic Treatment of Fabry Disease Using a Novel AAV9 Vector Expressing \u03b1-Galactosidase A","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2020.10.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s).","name":"copyright","label":"Copyright"}]}}